Biogen’s $900 million settlement signals scrutiny on speaker fees
Pharmaceutical Technology
OCTOBER 5, 2022
In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings. Ferry explains, “The government deems that [special fraud alert] as public notice to the industry that they are concerned about these public programs.”.
59 
Let's personalize your content